Hall Brett Matthew Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
4
Insider Buys Sum
$58,620.42
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Hall Brett Matthew

According to the SEC Form 4 filings, Hall Brett Matthew, being in a position of

  1. CHIEF SCIENTIFIC OFFICER at Immuneering Corporation,
    оver the last 12 months, has bought 8333 shares for $35,547, and sold 0 shares,
    over all time since 2021-08-03, has bought 33709 shares for $128,784, and sold 0 shares.

Biography of Hall Brett Matthew

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $35,5472100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2026-06-15PurchaseImmuneering Corporation
IMRX
CHIEF SCIENTIFIC OFFICER
6,035
0.0165%
$4.15$25,045+6.09%
2026-01-15PurchaseImmuneering Corporation
IMRX
CHIEF SCIENTIFIC OFFICER
2,298
0.0062%
$4.57$10,502+6.9%
2025-06-23PurchaseImmuneering Corporation
IMRX
CHIEF SCIENTIFIC OFFICER
6,007
0.0166%
$2.43$14,596+115.98%
2025-06-20PurchaseImmuneering Corporation
IMRX
CHIEF SCIENTIFIC OFFICER
7,415
0.0217%
$2.70$20,020+106.84%
2024-03-20PurchaseImmuneering Corporation
IMRX
CHIEF SCIENTIFIC OFFICER
7,000
0.0246%
$2.86$20,020-37.23%
2022-05-25PurchaseImmuneering Corporation
IMRX
CHIEF SCIENTIFIC OFFICER
2,551
0.0097%
$3.92$10,000+74.81%
2022-03-23PurchaseImmuneering Corporation
IMRX
CHIEF SCIENTIFIC OFFICER
1,050
0.0041%
$7.91$8,306-18.85%
2021-08-03PurchaseImmuneering Corporation
IMRX
Chief Scientific Officer
1,353
0.0058%
$15.00$20,295-47.84%
Total: 8
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.